TTD | Drug: D09XRQ

Drug General Information
Drug ID	D09XRQ
Former ID	DIB004526
Drug Name	HCBE-11
Drug Type	Antibody
Indication	Cancer [ICD9: 140-229; ICD10:C00-C96]		Phase 1	[521633]
Company	Biogen Inc
Target and Pathway
Target(s)	Lymphotoxin beta receptor	Target Info		[531813]
KEGG Pathway	Cytokine-cytokine receptor interaction
	NF-kappa B signaling pathway
	HIF-1 signaling pathway
	Intestinal immune network for IgA production
	HTLV-I infection
	Viral carcinogenesis
Reactome	TNFR2 non-canonical NF-kB pathway
Reactome	TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway
References
Ref 521633	ClinicalTrials.gov (NCT00105170) Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 531813	Lymphotoxin beta receptor activation on macrophages induces cross-tolerance to TLR4 and TLR9 ligands. J Immunol. 2012 Apr 1;188(7):3426-33.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Drug Information